COLL
Collegium PharmaceuticalBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
The strongest supported bull read is that Collegium entered Q2 with a still-growing base business, then added AZSTARYS with an immediate guidance raise, giving the company a broader ADHD platform and a longer revenue runway. [#SEC-8K-2026-05-07][#IR-2026-05-12]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
AZSTARYS integration may fail to deliver the expected revenue ramp, immediate accretion, or >$50M run-rate synergies within management’s timeline.
Momentum
26
Value
71
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.00 · Bull $52.00 · Bear $29.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $53.60
Why
Momentum26 · Δ7d -36.2
Value71 · Δ7d -0.2
Sentiment64 · Δ7d -7.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
26
26% active weight
Current posture
7d trendSoftening
Δ7d
-36.2
Δ21d
-4.1
Value
71
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.1
Sentiment
64
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.0
Δ21d
-22.2
Why this grade
Composite grade B. Momentum 26.0 / Value 71.5 / Sentiment 64.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.17B
Beta
0.65
Shares Out
32.43M
P/E (TTM)
28.5
P/S (TTM)
1.91
P/FCF (TTM)
4.99
Rev YoY
+8.9%
EPS YoY
+442.4%
Gross Margin
+60.7%
Op Margin
+20.7%
Net Debt
$529.9M
Current Ratio
1.71
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology